Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia.
BACKGROUND
The use at bedside of C-reactive protein (CRP), procalcitonin (PCT) or mid-regional pro-atrial natriuretic peptide (ANP) has been advocated to help management of patients with community-acquired pneumonia (CAP) in emergency medicine.


OBJECTIVE
To assess the effectiveness of CRP, PCT, and ANP measures in assisting emergency physicians deciding hospital admission for CAP with low risk of complication.


METHODS
Multicenter, prospective, observational study with blind evaluation.


METHODS
Emergency departments of 12 French hospitals.


METHODS
Five hundred forty-nine consecutive, immunocompetent adult patients with mild CAP.


METHODS
Centralized and blind measure of baseline CRP, PCT, and ANP; sensitivity, specificity, and positive and negative likelihood ratios for determining hospital admission. Gold standard for admission was defined by experts' advice combined with admission requirement or death at 28 days. Optimal threshold values were determined by receiver operating characteristic (ROC) curves, and area under curve (AUC) of the three biomarkers was compared.


RESULTS
According to gold standard, 310 (56%) patients required admission and 239 (44%) needed to be discharged. PCT and ANP levels increased with Pneumonia Severity Index risk categories. ANP (AUC 0.76 [95% CI 0.72-0.80]) more accurately predicted admission requirement than did PCT (AUC 0.65 [95% CI 0.61-0.70]) or CRP (AUC 0.59 [95% CI 0.54-0.64]) (both p values <0.01). We determined that 135 pmol/L was a threshold for ANP level to discriminate admission requirement (positive likelihood ratio 7.45 [95% CI 4.22-8.16]).


CONCLUSIONS
In a selected population of CAP with low risk of complication, a single ANP measurement was more accurate than CRP and PCT to predict appropriate admission. These results should be confirmed by additional studies.
Department of Emergency Medicine, Hôpital Cochin, APHP, 27 rue du Faubourg Saint-Jacques, Paris Cedex 14, France. yann-erick.claessens@cch.aphp.fr
Yann-Erick
YE
Claessens
Thierry
T
Mathevon
Gérald
G
Kierzek
Sophie
S
Grabar
David
D
Jegou
Eric
E
Batard
Clarisse
C
Loyer
Alain
A
Davido
Pierre
P
Hausfater
Hélène
H
Robert
Leila
L
Lavagna-Perez
Bruno
B
Bernot
Patrick
P
Plaisance
Christophe
C
Leroy
Bertrand
B
Renaud
D000328:Adult; D009320:Atrial Natriuretic Factor / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis*; D002116:Calcitonin / Q000097:blood*; D015740:Calcitonin Gene-Related Peptide; D017714:Community-Acquired Infections / Q000097:blood* / Q000000981:diagnostic imaging; D004636:Emergency Service, Hospital; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010343:Patient Admission; D011014:Pneumonia / Q000097:blood* / Q000000981:diagnostic imaging; D011379:Prognosis; D011446:Prospective Studies; D011498:Protein Precursors / Q000097:blood*; D011859:Radiography; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index
D015415:Biomarkers; C000606589:CALCA protein, human; D011498:Protein Precursors; D009320:Atrial Natriuretic Factor; D002116:Calcitonin; D002097:C-Reactive Protein; D015740:Calcitonin Gene-Related Peptide